Cempra, Inc. (CEMP)

[Johnny_C]

On the optimistic side, if one treats this as a brand new company, Melinta could see a pretty good spike if Barda funds the Soli trial.

For one, it is well established this is a new class antibiotic and is incredibly effective.

The liver issues are most likely overblown. I am not to high on Baxdela being launched and I doubt they will reach projected 400 mil in sales within 3 to 5 years but by the time Soli is approved they will have a seasoned sales force.

Within a year they will need more money, a couple hundred mil doesn’t last long when you launch a new drug.

There are other small catalysts that could help the news cycle but Soli is still the prize.